



residual_disease
cycles_combined
anatomic_subdivision
race
radiotherapy
grade
figo_stage
year_of_diagnosis
age_at_diagnosis
chemo_combined
hormone_therapy
bevacizumab
vital_status
surv_time

1
1
1
1
1
1
1
1
1
1
1
1
2
2
2
2
3
4
5
6
9
16
22
24
306

Band  Good  OK

CXCL10_IFN_TAMs_group
LILRA4_RB_TAMs_group
HSPA6_HSP_TAMs_group
TNFAIP6_Inflam_TAMs_group
LYVE1_RTM_TAMs_group
MT1H_MT_TAMs_group
TOP2A_Prolif_TAMs_group
CCL3L1_Inflam_TAMs_group
HLA_DPB1_Reg_TAMs_group
APOE_LP_TAMs_group
surv_time
vital_status
bevacizumab
hormone_therapy
chemo_combined
age_at_diagnosis
year_of_diagnosis
figo_stage
grade
radiotherapy
race
anatomic_subdivision
cycles_combined
residual_disease

0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0.73%
1.95%
2.44%
3.17%
5.85%
8.29%
10%

Total number of missing values